DB:015

Stock Analysis Report

Executive Summary

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has Aileron Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 015's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.4%

15

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-82.4%

15

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 015 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 015 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

15IndustryMarket
7 Day1.4%11.2%7.3%
30 Day-41.4%-5.3%-17.9%
90 Day-46.4%-21.9%-25.8%
1 Year-82.4%-82.4%-4.9%-5.1%-15.1%-17.7%
3 Yearn/a17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Aileron Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Aileron Therapeutics undervalued compared to its fair value and its price relative to the market?

0.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 015's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 015's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 015 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 015 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 015's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 015 is good value based on its PB Ratio (0.4x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Aileron Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-9.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 015 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 015 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 015 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 015's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 015's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 015's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Aileron Therapeutics performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 015 is currently unprofitable.

Growing Profit Margin: 015 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 015 is unprofitable, and losses have increased over the past 5 years at a rate of -20.7% per year.

Accelerating Growth: Unable to compare 015's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 015 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 015 has a negative Return on Equity (-127.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is Aileron Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 015's short term assets ($26.5M) exceed its short term liabilities ($6.4M).

Long Term Liabilities: 015's short term assets ($26.5M) exceed its long term liabilities ($4.7M).


Debt to Equity History and Analysis

Debt Level: 015 is debt free.

Reducing Debt: 015 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 015 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 015's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 015 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 015 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Aileron Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 015's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 015's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 015's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 015's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 015's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

Alves Aivado (49yo)

1.5s

Tenure

US$1,463,705

Compensation

Dr. Manuel C. Aivado, also known as Alves, M.D., Ph.D., has been President, Chief Executive Officer and Director of Aileron Therapeutics, Inc. since September 6, 2018. Dr. Aivado served as Chief Medical Of ...


CEO Compensation Analysis

Compensation vs Market: Alves's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Alves's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Manuel Aivado
President1.5yrsUS$1.46m0.0036% $325.9
Vojislav Vukovic
Senior VP & Chief Medical Officer1.33yrsUS$760.04k0.27% $24.4k
Richard Wanstall
SVP, CFO & Treasurer0.50yrno datano data
D. Annis
Senior Vice President of Research1.33yrsno data0.027% $2.5k
Kathryn Gregory
Senior VP & Chief Business Officer1yrno data0.16% $14.6k

1.3yrs

Average Tenure

50yo

Average Age

Experienced Management: 015's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Manuel Aivado
President1.5yrsUS$1.46m0.0036% $325.9
Josef von Rickenbach
Director0.75yrno data0.78% $71.0k
William McKee
Director0.75yrno datano data
Robert Grubbs
Member of Scientific Advisory Boardno datano datano data
David Nathan
Member of Advisory Board12.42yrsno datano data
Reinhard Ambros
Lead Director2yrsUS$109.35kno data
Michael Kastan
Chairman of Scientific Advisory Boardno datano datano data
Stephen Fesik
Member of Advisory Boardno datano datano data
Loren Walensky
Chairman of Scientific Advisory Boardno datano datano data
Jeffrey Bailey
Chairman of the Board2yrsUS$214.31k0.27% $24.4k

1.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 015's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.1%.


Top Shareholders

Company Information

Aileron Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Aileron Therapeutics, Inc.
  • Ticker: 15
  • Exchange: DB
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.037m
  • Listing Market Cap: US$9.052m
  • Shares outstanding: 27.81m
  • Website: https://www.aileronrx.com

Number of Employees


Location

  • Aileron Therapeutics, Inc.
  • 490 Arsenal Way
  • Suite 210
  • Watertown
  • Massachusetts
  • 2472
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
15DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2017
ALRNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2017

Biography

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company’s lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 00:19
End of Day Share Price2020/03/27 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.